OBJECTIVE: Pregnancy is a common indication for initiation of highly active antiretroviral therapy (HAART) in sub-Saharan Africa. Our objective was to evaluate how pregnancy at treatment initiation predicts virologic response to HAART. METHODS: We evaluated an open cohort of 9173 patients who initiated HAART between April 2004 and September 2009 in the Themba Lethu Clinic in Johannesburg, South Africa. Risk ratios were estimated using log-binomial regression; hazard ratios were estimated using Cox proportional hazards models; time ratios were estimated using accelerated failure time models. We controlled for calendar date, age, ethnicity, employment status, history of smoking, tuberculosis, WHO stage, weight, body mass index, hemoglobin, CD4 count and CD4 percent, and whether clinical care was free. Extensive sensitivity and secondary analyses were performed. RESULTS: During follow-up, 822 nonpregnant women and 70 pregnant women experienced virologic failure. In adjusted analyses, pregnancy at baseline was associated with reduced risk of virologic failure by 6 months [risk ratio 0.66, 95% confidence limits (CL): 0.35 to 1.22] and with reduced hazard of virologic failure over follow-up (hazard ratio: 0.69, 95% CL: 0.50 to 0.95). The adjusted time ratio for failure was 1.44 (95% CL: 1.13 to 1.84), indicating 44% longer time to event among women pregnant at baseline. Sensitivity analyses generally confirmed main findings. CONCLUSIONS: Pregnancy at HAART initiation is not associated with increased risk of virologic failure at 6 months or during longer follow-up.
OBJECTIVE: Pregnancy is a common indication for initiation of highly active antiretroviral therapy (HAART) in sub-Saharan Africa. Our objective was to evaluate how pregnancy at treatment initiation predicts virologic response to HAART. METHODS: We evaluated an open cohort of 9173 patients who initiated HAART between April 2004 and September 2009 in the Themba Lethu Clinic in Johannesburg, South Africa. Risk ratios were estimated using log-binomial regression; hazard ratios were estimated using Cox proportional hazards models; time ratios were estimated using accelerated failure time models. We controlled for calendar date, age, ethnicity, employment status, history of smoking, tuberculosis, WHO stage, weight, body mass index, hemoglobin, CD4 count and CD4 percent, and whether clinical care was free. Extensive sensitivity and secondary analyses were performed. RESULTS: During follow-up, 822 nonpregnant women and 70 pregnant women experienced virologic failure. In adjusted analyses, pregnancy at baseline was associated with reduced risk of virologic failure by 6 months [risk ratio 0.66, 95% confidence limits (CL): 0.35 to 1.22] and with reduced hazard of virologic failure over follow-up (hazard ratio: 0.69, 95% CL: 0.50 to 0.95). The adjusted time ratio for failure was 1.44 (95% CL: 1.13 to 1.84), indicating 44% longer time to event among women pregnant at baseline. Sensitivity analyses generally confirmed main findings. CONCLUSIONS: Pregnancy at HAART initiation is not associated with increased risk of virologic failure at 6 months or during longer follow-up.
Authors: Audrey E Pettifor; Helen V Rees; Immo Kleinschmidt; Annie E Steffenson; Catherine MacPhail; Lindiwe Hlongwa-Madikizela; Kerry Vermaak; Nancy S Padian Journal: AIDS Date: 2005-09-23 Impact factor: 4.177
Authors: Daniel Westreich; Patrick MacPhail; Annelies Van Rie; Babatyi Malope-Kgokong; Prudence Ive; Dennis Rubel; Ronan Boulmé; Joseph Eron; Ian Sanne Journal: AIDS Date: 2009-03-27 Impact factor: 4.177
Authors: Daniel Westreich; Stephen R Cole; Shashi Nagar; Mhairi Maskew; Charles van der Horst; Ian Sanne Journal: PLoS One Date: 2011-08-02 Impact factor: 3.240
Authors: Cassidy E Henegar; Daniel J Westreich; Mhairi Maskew; William C Miller; M Alan Brookhart; Annelies Van Rie Journal: J Acquir Immune Defic Syndr Date: 2015-04-01 Impact factor: 3.731
Authors: Paula D Strassle; Jacqueline E Rudolph; Bryna J Harrington; Sara N Levintow Journal: J Acquir Immune Defic Syndr Date: 2017-06-01 Impact factor: 3.731
Authors: Risa M Hoffman; Erin Leister; Deborah Kacanek; David E Shapiro; Jennifer S Read; Yvonne Bryson; Judith S Currier Journal: J Acquir Immune Defic Syndr Date: 2013-08-15 Impact factor: 3.731
Authors: Angela M Bengtson; Carla J Chibwesha; Daniel Westreich; Mwangelwa Mubiana-Mbewe; Benjamin H Chi; William C Miller; Muntanga Mapani; Brian W Pence; Patrick Musonda; Jeffrey Sa Stringer; Audrey Pettifor Journal: AIDS Care Date: 2016-02-17
Authors: Charles B Holmes; Constantin T Yiannoutsos; Batya Elul; Elizabeth Bukusi; John Ssali; Andrew Kambugu; Beverly S Musick; Craig Cohen; Carolyn Williams; Lameck Diero; Nancy Padian; Kara K Wools-Kaloustian Journal: PLoS One Date: 2018-01-17 Impact factor: 3.240